Hospital
Prohealth Waukesha Memorial Hospital, INC.
Prohealth Waukesha Memorial Hospital, INC. was paid $21.39M by Medicaid between Jan 2018 and Dec 2024, across 363 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10.0% of everything it billed.
33Billing provider infoPROHEALTH WAUKESHA MEMORIAL HOSPITAL, INC.
WAUKESHA, WI 53188
WAUKESHA, WI 53188
33aNPI1629056890assigned 01/06/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$21.39M
24GClaims1,287,422
24DCodes billed363
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 162,925 | $3.38M | |
| 2019 | 167,539 | $3.15M | |
| 2020 | 154,932 | $2.93M | |
| 2021 | 194,596 | $3.15M | |
| 2022 | 216,347 | $3.02M | |
| 2023 | 226,606 | $3.13M | |
| 2024incomplete | 164,477 | $2.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10.0% | 37,183 | 30,977 | $2.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.2% | 28,553 | 23,615 | $1.33M |
| 80053 | Comprehensive metabolic panel | 4.7% | 69,280 | 51,558 | $997K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.5% | 14,505 | 12,325 | $972K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.5% | 8,822 | 6,072 | $953K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.0% | 26,544 | 10,454 | $651K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 10,717 | 8,809 | $499K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 8,769 | 5,485 | $486K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 7,435 | 6,266 | $432K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.0% | 23,153 | 7,678 | $425K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 7,717 | 6,268 | $398K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 70,227 | 51,318 | $391K |
351 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.8% | 13,967 | $385K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.7% | 6,028 | $368K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 6,027 | $359K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.6% | 14,040 | $349K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 13,904 | $347K |
| G0378 | Hospital observation service, per hour | 1.6% | 6,771 | $345K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 7,250 | $338K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.5% | 6,285 | $313K |
| 80050 | General health panel | 1.4% | 11,946 | $305K |
| 99285 | Emergency room visit (most serious) | 1.4% | 9,020 | $297K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 3,786 | $243K |
| 80061 | Lipid panel | 1.1% | 22,679 | $227K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 9,754 | $212K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,175 | $211K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,567 | $198K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,481 | $194K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,365 | $186K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,213 | $183K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,231 | $180K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,605 | $180K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,053 | $179K |
| 59025 | Fetal non-stress test | <1% | 2,537 | $174K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 8,915 | $174K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,959 | $156K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,893 | $148K |
| 84702 | <1% | 8,330 | $141K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,440 | $140K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,197 | $138K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,292 | $138K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 893 | $137K |
| 87070 | <1% | 11,938 | $129K | |
| 97162 | <1% | 4,344 | $125K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,447 | $124K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,699 | $124K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,809 | $121K |
| 84484 | <1% | 14,701 | $114K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,950 | $103K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,292 | $101K |
| 85027 | <1% | 16,556 | $90K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,257 | $85K |
| 82947 | <1% | 12,915 | $84K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,934 | $82K |
| 87653 | <1% | 2,301 | $73K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,278 | $72K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,016 | $71K |
| 81001 | <1% | 24,414 | $70K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,694 | $68K |
| 76830 | Ultrasound, transvaginal | <1% | 1,949 | $66K |
| 80081 | <1% | 975 | $66K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,520 | $63K |
| 84703 | <1% | 6,037 | $62K | |
| 82607 | <1% | 5,551 | $61K | |
| 87808 | <1% | 5,017 | $59K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,132 | $58K |
| 82728 | <1% | 5,812 | $57K | |
| 84439 | <1% | 6,922 | $56K | |
| 64615 | <1% | 571 | $55K | |
| 85610 | <1% | 7,911 | $55K | |
| 96415 | <1% | 794 | $54K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,187 | $53K |
| 83690 | <1% | 10,434 | $53K | |
| 83735 | <1% | 11,877 | $51K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 566 | $50K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 373 | $48K |
| 87186 | <1% | 7,512 | $48K | |
| 93971 | <1% | 1,848 | $47K | |
| 84146 | <1% | 2,506 | $46K | |
| 87077 | <1% | 6,618 | $45K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,460 | $43K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,960 | $42K |
| 86480 | <1% | 923 | $42K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 755 | $41K |
| 93017 | <1% | 1,054 | $41K | |
| 96367 | <1% | 1,049 | $40K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,913 | $39K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,349 | $39K |
| 82247 | <1% | 1,348 | $39K | |
| 76801 | <1% | 932 | $38K | |
| 86769 | <1% | 1,145 | $38K | |
| 81025 | <1% | 2,874 | $36K | |
| 86803 | <1% | 3,180 | $36K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 530 | $36K |
| 83880 | <1% | 1,762 | $34K | |
| 97163 | <1% | 1,472 | $33K | |
| 84153 | <1% | 2,573 | $32K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,975 | $32K |
| 82550 | <1% | 6,935 | $31K | |
| 83655 | <1% | 2,314 | $30K | |
| 87210 | <1% | 5,052 | $30K | |
| 85379 | <1% | 3,709 | $27K | |
| 97113 | <1% | 590 | $26K | |
| 83550 | <1% | 4,727 | $26K | |
| 87088 | <1% | 4,123 | $25K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,649 | $25K |
| 80047 | <1% | 1,396 | $24K | |
| 80164 | <1% | 1,704 | $24K | |
| 80076 | <1% | 2,505 | $23K | |
| 86780 | <1% | 2,684 | $23K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 788 | $22K |
| 83540 | <1% | 5,278 | $22K | |
| 97166 | <1% | 1,054 | $22K | |
| 12001 | <1% | 283 | $21K | |
| 82043 | <1% | 4,353 | $21K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 471 | $19K |
| 82570 | <1% | 4,898 | $19K | |
| 97161 | <1% | 530 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,153 | $19K |
| 87428 | <1% | 558 | $19K | |
| 82950 | <1% | 1,338 | $18K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 335 | $18K |
| 82746 | <1% | 1,965 | $18K | |
| 83970 | <1% | 700 | $17K | |
| 86850 | <1% | 1,849 | $17K | |
| 80074 | <1% | 555 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 19,013 | $17K |
| H2012 | Behavioral health day treatment, per hour | <1% | 4,392 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,162 | $16K |
| 82565 | <1% | 2,047 | $16K | |
| 87040 | <1% | 2,289 | $16K | |
| 86140 | <1% | 3,923 | $15K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 327 | $15K |
| 82330 | <1% | 1,777 | $15K | |
| 87205 | <1% | 4,472 | $14K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,505 | $14K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 40 | $14K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 528 | $14K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 93 | $14K |
| 84403 | <1% | 786 | $13K | |
| 86038 | <1% | 1,426 | $13K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 72 | $13K |
| 82784 | <1% | 1,728 | $12K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,753 | $12K |
| 83516 | <1% | 1,081 | $11K | |
| 80320 | <1% | 4,439 | $11K | |
| 84132 | <1% | 2,082 | $11K | |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 31 | $10K |
| 84100 | <1% | 3,024 | $10K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 254 | $10K |
| 87529 | <1% | 199 | $9K | |
| 71250 | <1% | 356 | $9K | |
| 87147 | <1% | 2,179 | $9K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 22 | $9K |
| 87081 | <1% | 882 | $9K | |
| 83001 | <1% | 611 | $9K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 163 | $8K |
| 85652 | <1% | 4,032 | $8K | |
| 88304 | <1% | 1,084 | $8K | |
| 76536 | <1% | 225 | $8K | |
| 85007 | <1% | 2,316 | $8K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 83,973 | $8K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 117 | $7K |
| 83605 | <1% | 932 | $7K | |
| 97035 | <1% | 713 | $7K | |
| 81003 | <1% | 2,285 | $7K | |
| 70486 | <1% | 247 | $6K | |
| 95886 | <1% | 96 | $6K | |
| 83615 | <1% | 2,455 | $6K | |
| 84156 | <1% | 1,769 | $6K | |
| 76642 | <1% | 434 | $6K | |
| 88342 | <1% | 1,411 | $6K | |
| 95806 | <1% | 245 | $5K | |
| 87150 | <1% | 155 | $5K | |
| 87807 | <1% | 356 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,486 | $5K |
| 80178 | <1% | 776 | $5K | |
| 86901 | <1% | 2,291 | $5K | |
| 72100 | <1% | 1,378 | $5K | |
| 76770 | <1% | 138 | $5K | |
| 82248 | <1% | 1,310 | $4K | |
| 86900 | <1% | 1,983 | $4K | |
| 94060 | <1% | 144 | $4K | |
| 86618 | <1% | 314 | $4K | |
| 86364 | <1% | 495 | $4K | |
| 86003 | <1% | 848 | $4K | |
| 12011 | <1% | 60 | $4K | |
| 74018 | <1% | 970 | $4K | |
| 93970 | <1% | 126 | $4K | |
| 84460 | <1% | 1,027 | $4K | |
| 80329 | <1% | 4,121 | $3K | |
| 94770 | <1% | 52 | $3K | |
| 87102 | <1% | 489 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 79 | $3K |
| 97165 | <1% | 103 | $3K | |
| 87340 | <1% | 411 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 90 | $3K |
| 84450 | <1% | 866 | $3K | |
| 90715 | <1% | 529 | $3K | |
| 84550 | <1% | 794 | $3K | |
| 73610 | <1% | 1,120 | $3K | |
| 64400 | <1% | 17 | $3K | |
| 36430 | <1% | 18 | $3K | |
| 72141 | <1% | 82 | $2K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 27 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 60 | $2K |
| 93225 | <1% | 91 | $2K | |
| 96376 | <1% | 4,848 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 375 | $2K |
| 84481 | <1% | 185 | $2K | |
| 86376 | <1% | 210 | $2K | |
| 73630 | <1% | 1,074 | $2K | |
| 73502 | <1% | 510 | $2K | |
| 85018 | <1% | 1,047 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 19 | $2K |
| 12002 | <1% | 50 | $2K | |
| 97032 | <1% | 161 | $2K | |
| 73562 | <1% | 1,192 | $2K | |
| 86431 | <1% | 448 | $2K | |
| 86706 | <1% | 197 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $2K |
| 87493 | <1% | 58 | $2K | |
| 83721 | <1% | 308 | $2K | |
| 93880 | <1% | 63 | $2K | |
| 97167 | <1% | 105 | $1K | |
| 88307 | <1% | 257 | $1K | |
| 82803 | <1% | 75 | $1K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 34 | $1K |
| 73130 | <1% | 561 | $1K | |
| 82272 | <1% | 264 | $1K | |
| 82670 | <1% | 60 | $1K | |
| 62323 | <1% | 17 | $1K | |
| 84165 | <1% | 200 | $1K | |
| 88341 | <1% | 151 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 26 | $1K |
| 82553 | <1% | 231 | $1K | |
| 73030 | <1% | 1,052 | $1K | |
| 85730 | <1% | 225 | $990.28 | |
| 82533 | <1% | 101 | $957.00 | |
| 82040 | <1% | 76 | $913.05 | |
| 90686 | <1% | 154 | $907.29 | |
| 85046 | <1% | 232 | $890.01 | |
| 77066 | Tomosynthesis, mammo | <1% | 89 | $838.10 |
| 76813 | <1% | 79 | $728.00 | |
| 87563 | <1% | 39 | $662.44 | |
| 87075 | <1% | 116 | $648.09 | |
| 36591 | <1% | 74 | $594.03 | |
| 76982 | <1% | 69 | $562.57 | |
| 93296 | <1% | 58 | $560.56 | |
| 93226 | <1% | 91 | $545.45 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 248 | $533.41 |
| 99454 | <1% | 113 | $506.61 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 736 | $490.44 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,870 | $484.28 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,326 | $467.68 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,027 | $462.37 |
| 88142 | <1% | 26 | $434.19 | |
| 86704 | <1% | 42 | $428.50 | |
| 85014 | <1% | 303 | $420.94 | |
| 73110 | <1% | 213 | $403.76 | |
| G0008 | Administration of influenza virus vaccine | <1% | 326 | $393.44 |
| 83520 | <1% | 41 | $386.40 | |
| 84480 | <1% | 32 | $372.63 | |
| 76870 | <1% | 12 | $366.85 | |
| 94729 | <1% | 82 | $360.34 | |
| 81002 | <1% | 48 | $355.31 | |
| 93270 | <1% | 28 | $336.71 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 222 | $321.19 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,405 | $315.21 |
| 36416 | <1% | 682 | $315.10 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,953 | $315.04 |
| 93922 | <1% | 14 | $308.90 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 942 | $292.94 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 81 | $272.46 |
| 88312 | <1% | 137 | $265.03 | |
| 84145 | <1% | 16 | $262.42 | |
| 84295 | <1% | 105 | $252.22 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,490 | $208.16 |
| 82378 | <1% | 15 | $179.47 | |
| 84466 | <1% | 13 | $173.20 | |
| 88112 | <1% | 15 | $163.91 | |
| 80175 | <1% | 14 | $136.72 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 22 | $133.09 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 128 | $126.29 |
| 86308 | <1% | 29 | $123.94 | |
| 72040 | <1% | 99 | $112.40 | |
| 84155 | <1% | 34 | $108.26 | |
| 82140 | <1% | 14 | $106.46 | |
| 82785 | <1% | 16 | $103.21 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 24 | $102.70 |
| 73560 | <1% | 49 | $87.80 | |
| 94726 | <1% | 42 | $85.54 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,809 | $80.40 |
| 74019 | <1% | 239 | $77.34 | |
| 97116 | <1% | 38 | $68.40 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 40 | $64.92 |
| G0009 | Administration of pneumococcal vaccine | <1% | 82 | $62.11 |
| 72170 | <1% | 46 | $55.09 | |
| 95800 | <1% | 86 | $54.94 | |
| 94644 | <1% | 313 | $43.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,101 | $39.71 |
| 51798 | <1% | 154 | $39.34 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,236 | $36.27 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,057 | $33.36 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 513 | $27.94 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,446 | $27.24 |
| 99152 | <1% | 260 | $24.92 | |
| 97602 | <1% | 26 | $24.62 | |
| 73080 | <1% | 58 | $23.42 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 334 | $22.38 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 155 | $22.13 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,410 | $21.55 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,527 | $20.88 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 116 | $13.34 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 32 | $12.67 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 435 | $11.31 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 78 | $10.52 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,263 | $8.47 |
| 73140 | <1% | 17 | $8.40 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 380 | $8.12 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,215 | $7.77 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,259 | $6.31 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,429 | $4.16 |
| 94760 | <1% | 1,910 | $3.58 | |
| J2704 | Injection, propofol, 10 mg | <1% | 548 | $3.39 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,290 | $3.23 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 252 | $2.73 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,933 | $2.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,346 | $2.61 |
| 86923 | <1% | 18 | $2.26 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 190 | $2.21 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 492 | $0.01 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 277 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 6,966 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 639 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 175 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 1,083 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 314 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 148 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 161 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 329 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 52 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 92 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 12 | $0.00 |
| 90662 | 0% | 12 | $0.00 | |
| 36592 | 0% | 12 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 6,809 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 1,513 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 28 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 46 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 101 | $0.00 |
| C1769 | Guide wire | 0% | 213 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 28 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 38 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 33 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 43 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 48 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 27 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 89 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 14 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 15 | $0.00 |
| 73090 | 0% | 18 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEDWARDS, SUSAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Prohealth Oconomowoc Memorial Hospital, INC. | Oconomowoc, WI | $2.33M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.